Huiqin Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Huiqin Xu has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
Niange Xia
Department of Neurology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, P.R. China
10 shared publicationsRongyuan Zheng
Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
10 shared publicationsXinshi Wang
Department of Neurology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, PR China
10 shared publicationsYanru Du
Department of Neurology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, PR China
10 shared publicationsSiqi Ding
Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
9 shared publicationsZhenguo Zhu
Department of Neurology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, P.R. China
9 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1904036
Plasma FGF21 is associated with intracranial atherosclerotic stenosis in patients with type 2 diabetes mellitus
Introduction: FGF21 is associated with atherosclerosis and the anatomical severity of coronary artery disease. No study has explored the relationship between FGF21 and intracranial atherosclerotic stenosis. The purpose of this study is to explore the association between FGF21 and intracranial atherosclerotic stenosis in patients with type 2 diabetes mellitus. Methods: One hundred ten patients with type 2 diabetes were recruited. The levels of plasma FGF21 were measured by enzyme-linked immunosorbent assays. The severity of intracranial atherosclerotic stenosis was evaluated in strict accordance with the internationally recognized modified Warfarin-Aspirin Symptomatic Intracranial Disease criteria. Patients were categorized into three groups based on percent stenosis: no stenosis (0%), mild stenosis (1–49%), and moderate to severe stenosis (≥50%). Results: Plasma FGF21 level was different among no stenosis group, mild stenosis group and moderate to severe stenosis group (114.35 (105.35–124.04) vs. 124.81 (118.84–134.47) vs. 132.18 (120.43–150.05), H = 17.327, p < 0.001). FGF21 levels in the moderate-to-severe stenosis group were higher than those in the no stenosis + mild stenosis group (132.18 (120.43–150.05) vs. 122.44 (109.88–129.19), U = -3.138, p = 0.002). The highest tertile (T3) of FGF21 level (>129.55 ng/L) and lnFGF21 was associated with moderate to severe intracranial atherosclerotic stenosis in patients with T2DM after adjusting for age andα-glucosidase inhibitor use (OR = 6.453, 95% CI: 1.944–21.415, p = 0.002; OR = 2.191, 95% CI: 1.277–3.759, p = 0.004). Based on the receiver-operating characteristic (ROC) curve, the combination of lnFGF21, age, and α-glucosidase inhibitor use predicted moderate to severe intracranial atherosclerotic stenosis in patients with type 2 diabetes mellitus, with an area under the curve (AUC) of 0.768 (95% CI, 0.670–0.865). Bootstrap resampling with 1,000 replicates was performed for internal validation to assess model stability and calibration (bootstrap B = 1,000; MAE = 0.021, MSE = 0.00064, 90th percentile of absolute error = 0.038). Conclusion: We observed a significant cross-sectional association between plasma FGF21 levels and intracranial atherosclerotic stenosis among patients with T2DM.
- 7 September 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1904036
Open AccessPlasma FGF21 is associated with intracranial atherosclerotic stenosis in patients with type 2 diabetes mellitus
Introduction: FGF21 is associated with atherosclerosis and the anatomical severity of coronary artery disease. No study has explored the relationship between FGF21 and intracranial atherosclerotic stenosis. The purpose of this study is to explore the association between FGF21 and intracranial atherosclerotic stenosis in patients with type 2 diabetes mellitus. Methods: One hundred ten patients with type 2 diabetes were recruited. The levels of plasma FGF21 were measured by enzyme-linked immunosorbent assays. The severity of intracranial atherosclerotic stenosis was evaluated in strict accordance with the internationally recognized modified Warfarin-Aspirin Symptomatic Intracranial Disease criteria. Patients were categorized into three groups based on percent stenosis: no stenosis (0%), mild stenosis (1–49%), and moderate to severe stenosis (≥50%). Results: Plasma FGF21 level was different among no stenosis group, mild stenosis group and moderate to severe stenosis group (114.35 (105.35–124.04) vs. 124.81 (118.84–134.47) vs. 132.18 (120.43–150.05), H = 17.327, p < 0.001). FGF21 levels in the moderate-to-severe stenosis group were higher than those in the no stenosis + mild stenosis group (132.18 (120.43–150.05) vs. 122.44 (109.88–129.19), U = -3.138, p = 0.002). The highest tertile (T3) of FGF21 level (>129.55 ng/L) and lnFGF21 was associated with moderate to severe intracranial atherosclerotic stenosis in patients with T2DM after adjusting for age andα-glucosidase inhibitor use (OR = 6.453, 95% CI: 1.944–21.415, p = 0.002; OR = 2.191, 95% CI: 1.277–3.759, p = 0.004). Based on the receiver-operating characteristic (ROC) curve, the combination of lnFGF21, age, and α-glucosidase inhibitor use predicted moderate to severe intracranial atherosclerotic stenosis in patients with type 2 diabetes mellitus, with an area under the curve (AUC) of 0.768 (95% CI, 0.670–0.865). Bootstrap resampling with 1,000 replicates was performed for internal validation to assess model stability and calibration (bootstrap B = 1,000; MAE = 0.021, MSE = 0.00064, 90th percentile of absolute error = 0.038). Conclusion: We observed a significant cross-sectional association between plasma FGF21 levels and intracranial atherosclerotic stenosis among patients with T2DM.
- 19 June 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 183, 111160
Validating the C-PHQ-9 suicide item against the C-NDDI-E for detecting suicidal ideation in Chinese adults with epilepsy
- 19 June 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 183, 111160
Validating the C-PHQ-9 suicide item against the C-NDDI-E for detecting suicidal ideation in Chinese adults with epilepsy
- Open Access
Early response rates with adjunctive cenobamate in uncontrolled focal seizures: Prospective analysis of a randomized, double‐blind, placebo‐controlled study in a multinational Asian population
Objective: To examine early responses to cenobamate therapy using prospective data from a dose–response study in Asian patients with focal seizures (YKP3089C035, C035) that employed a titration regimen starting at 12.5 mg/day. Methods: In Study C035, adults 18–70 years of age with uncontrolled focal seizures despite treatment with 1–3 antiseizure medications were randomized 1:1:1:1 to receive placebo or adjunctive cenobamate 100, 200, or 400 mg/day. The 24‐week double‐blind study included an 18‐week titration and 6‐week maintenance phase. During the first 8 weeks of titration (“early titration phase”), all cenobamate patients received the same dosing regimen: 12.5 mg/day for 2 weeks, 25 mg/day for 2 weeks, 50 mg/day for 2 weeks, and 100 mg/day for 2 weeks. Change in seizure frequency from baseline and responder rates were assessed at these 2‐week intervals for combined cenobamate dose groups vs placebo. Analyses were performed on the modified intent‐to‐treat maintenance (MITT‐M) population (≥1 study drug dose and seizure data in the maintenance phase); all patients completed early titration. Results: Of 519 patients randomized, 446 were included in the MITT‐M population (placebo n = 117, cenobamate n = 329). During Weeks 1–2, 3–4, 5–6, and 7–8 of titration, cenobamate patients experienced a median reduction in 28‐day seizure frequency of 16.0% (vs 20.0% placebo, p = .81), 27.3% (vs 22.2% placebo, p = .42), 42.9% (vs 15.4% placebo, p = .002), and 55.6% (vs 20.0% placebo, p < .001), respectively. During Weeks 5–6 and 7–8, the 100% responder rates for cenobamate 50 and 100 mg/day were 17.0% (vs 12.8% placebo, p = .29) and 26.7% (vs 8.5% placebo, p < .001), respectively. Significance: Statistically significant responses to cenobamate treatment occurred within the first 8 weeks of titration, including a 42.9% median reduction in 28‐day seizure frequency (Weeks 5–6) and a seizure‐free rate of 26.7% (Weeks 7–8). These data show that substantial seizure reductions occurred in many patients early during cenobamate titration.
Open AccessEarly response rates with adjunctive cenobamate in uncontrolled focal seizures: Prospective analysis of a randomized, double‐blind, placebo‐controlled study in a multinational Asian population
Objective: To examine early responses to cenobamate therapy using prospective data from a dose–response study in Asian patients with focal seizures (YKP3089C035, C035) that employed a titration regimen starting at 12.5 mg/day. Methods: In Study C035, adults 18–70 years of age with uncontrolled focal seizures despite treatment with 1–3 antiseizure medications were randomized 1:1:1:1 to receive placebo or adjunctive cenobamate 100, 200, or 400 mg/day. The 24‐week double‐blind study included an 18‐week titration and 6‐week maintenance phase. During the first 8 weeks of titration (“early titration phase”), all cenobamate patients received the same dosing regimen: 12.5 mg/day for 2 weeks, 25 mg/day for 2 weeks, 50 mg/day for 2 weeks, and 100 mg/day for 2 weeks. Change in seizure frequency from baseline and responder rates were assessed at these 2‐week intervals for combined cenobamate dose groups vs placebo. Analyses were performed on the modified intent‐to‐treat maintenance (MITT‐M) population (≥1 study drug dose and seizure data in the maintenance phase); all patients completed early titration. Results: Of 519 patients randomized, 446 were included in the MITT‐M population (placebo n = 117, cenobamate n = 329). During Weeks 1–2, 3–4, 5–6, and 7–8 of titration, cenobamate patients experienced a median reduction in 28‐day seizure frequency of 16.0% (vs 20.0% placebo, p = .81), 27.3% (vs 22.2% placebo, p = .42), 42.9% (vs 15.4% placebo, p = .002), and 55.6% (vs 20.0% placebo, p < .001), respectively. During Weeks 5–6 and 7–8, the 100% responder rates for cenobamate 50 and 100 mg/day were 17.0% (vs 12.8% placebo, p = .29) and 26.7% (vs 8.5% placebo, p < .001), respectively. Significance: Statistically significant responses to cenobamate treatment occurred within the first 8 weeks of titration, including a 42.9% median reduction in 28‐day seizure frequency (Weeks 5–6) and a seizure‐free rate of 26.7% (Weeks 7–8). These data show that substantial seizure reductions occurred in many patients early during cenobamate titration.
- Open Access
- 12 November 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 1-15
Disulfiram Prevents Blood-Brain Barrier Disruption in Epileptic Mice by Inhibiting Astrocyte Pyroptosis to Improve Seizure Activity
Epilepsy is a prevalent neurological disorder whose pathogenesis is closely associated with blood–brain barrier (BBB) disruption. Emerging evidence suggests that astrocytic pyroptosis may play a pivotal role in BBB impairment. Based on this, we propose two central hypotheses: (1) seizure activity triggers astrocytic pyroptosis and exacerbates BBB damage; (2) pharmacological inhibition of pyroptosis can restore BBB integrity and alleviate epileptic symptoms. This study established a kainic acid-induced mouse model of epilepsy and an in vitro BBB model. Cell pyroptosis was induced using LPS and ATP. The expression of BBB and pyroptosis-related proteins was assessed through Western blotting, immunofluorescence, and RT-PCR. Additionally, a pyroptosis inhibitor, disulfiram (DSF), was used to inhibit pyroptosis, and the therapeutic effects on epilepsy were evaluated through behavioral experiments, electroencephalography, and electron microscopy. BBB damage and pyroptosis were observed in the hippocampal tissue of mice following seizures, with immunofluorescence results indicating the occurrence of pyroptosis in astrocytes. In vitro experiments demonstrated that astrocyte pyroptosis leads to the downregulation of tight junction proteins in endothelial cells. Inhibition of pyroptosis by DSF improved the integrity of the BBB and resulted in reduced severity of seizure activity and improved cognitive function in mice. This study reveals the role of astrocyte pyroptosis in seizure activity and the consequent BBB damage. DSF mitigates seizure severity and cognitive impairment by inhibiting astrocyte pyroptosis and improving BBB integrity, offering new insights and targets for epilepsy treatment.
- 12 November 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 1-15
Open AccessDisulfiram Prevents Blood-Brain Barrier Disruption in Epileptic Mice by Inhibiting Astrocyte Pyroptosis to Improve Seizure Activity
Epilepsy is a prevalent neurological disorder whose pathogenesis is closely associated with blood–brain barrier (BBB) disruption. Emerging evidence suggests that astrocytic pyroptosis may play a pivotal role in BBB impairment. Based on this, we propose two central hypotheses: (1) seizure activity triggers astrocytic pyroptosis and exacerbates BBB damage; (2) pharmacological inhibition of pyroptosis can restore BBB integrity and alleviate epileptic symptoms. This study established a kainic acid-induced mouse model of epilepsy and an in vitro BBB model. Cell pyroptosis was induced using LPS and ATP. The expression of BBB and pyroptosis-related proteins was assessed through Western blotting, immunofluorescence, and RT-PCR. Additionally, a pyroptosis inhibitor, disulfiram (DSF), was used to inhibit pyroptosis, and the therapeutic effects on epilepsy were evaluated through behavioral experiments, electroencephalography, and electron microscopy. BBB damage and pyroptosis were observed in the hippocampal tissue of mice following seizures, with immunofluorescence results indicating the occurrence of pyroptosis in astrocytes. In vitro experiments demonstrated that astrocyte pyroptosis leads to the downregulation of tight junction proteins in endothelial cells. Inhibition of pyroptosis by DSF improved the integrity of the BBB and resulted in reduced severity of seizure activity and improved cognitive function in mice. This study reveals the role of astrocyte pyroptosis in seizure activity and the consequent BBB damage. DSF mitigates seizure severity and cognitive impairment by inhibiting astrocyte pyroptosis and improving BBB integrity, offering new insights and targets for epilepsy treatment.
- Open Access
- 21 October 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1134
FGF10 ameliorates epileptic seizures and related cognitive dysfunction via the FGFR2/CALB1 signaling pathway
Background Temporal lobe epilepsy (TLE) is frequently associated with cognitive impairments, such as memory deficits, attention disorders, and executive dysfunction. Given that these cognitive deficits are closely linked to neuronal loss in TLE, fibroblast growth factor 10 (FGF10), a molecule recognized for its neuroprotective properties, has emerged as a promising therapeutic candidate. The kainic acid (KA)-induced epilepsy model can replicate key pathological features of TLE. The study aims to investigate the potential role of FGF10 in TLE, using the KA-induced model as an experimental framework. Methods We induced epilepsy in mice using KA and administered intranasal FGF10 over 14 days or delivered an AAV virus to overexpress FGF10. Seizure activity was monitored via video-electroencephalography (EEG), and behavioral tests were conducted to assess spatial cognition, anxiety-related behaviors, and depressive-like behaviors. Neuronal damage was evaluated using Nissl staining and TUNEL staining. To explore the molecular mechanisms underlying FGF10's effects, we performed RNA sequencing, followed by validation with Western blotting and qRT-PCR. Additionally, we generated FGFR2 conditional knockout (cKO) mice to investigate the role of FGF10-FGFR2 signaling. Results FGF10 treatment significantly reduced seizure frequency and improved epilepsy-related cognitive deficits. It also exerted neuroprotective effects, as evidenced by reduced neuronal death in KA-induced epileptic mice. RNA sequencing revealed decreased CALB1 levels in the hippocampal dentate gyrus of epileptic mice, which were restored following FGF10 administration. Crucially, the therapeutic benefits of FGF10 were abolished in FGFR2-cKO mice, indicating that FGFR2 is essential for FGF10's effects. Conclusions Our findings demonstrate that FGF10 alleviates seizures and cognitive dysfunction in epilepsy, likely through FGFR2-dependent mechanisms involving CALB1 modulation. These results highlight FGF10 as a potential therapeutic target for epilepsy, offering a novel strategy for improving treatment outcomes in patients with TLE.
- 21 October 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1134
Open AccessFGF10 ameliorates epileptic seizures and related cognitive dysfunction via the FGFR2/CALB1 signaling pathway
Background Temporal lobe epilepsy (TLE) is frequently associated with cognitive impairments, such as memory deficits, attention disorders, and executive dysfunction. Given that these cognitive deficits are closely linked to neuronal loss in TLE, fibroblast growth factor 10 (FGF10), a molecule recognized for its neuroprotective properties, has emerged as a promising therapeutic candidate. The kainic acid (KA)-induced epilepsy model can replicate key pathological features of TLE. The study aims to investigate the potential role of FGF10 in TLE, using the KA-induced model as an experimental framework. Methods We induced epilepsy in mice using KA and administered intranasal FGF10 over 14 days or delivered an AAV virus to overexpress FGF10. Seizure activity was monitored via video-electroencephalography (EEG), and behavioral tests were conducted to assess spatial cognition, anxiety-related behaviors, and depressive-like behaviors. Neuronal damage was evaluated using Nissl staining and TUNEL staining. To explore the molecular mechanisms underlying FGF10's effects, we performed RNA sequencing, followed by validation with Western blotting and qRT-PCR. Additionally, we generated FGFR2 conditional knockout (cKO) mice to investigate the role of FGF10-FGFR2 signaling. Results FGF10 treatment significantly reduced seizure frequency and improved epilepsy-related cognitive deficits. It also exerted neuroprotective effects, as evidenced by reduced neuronal death in KA-induced epileptic mice. RNA sequencing revealed decreased CALB1 levels in the hippocampal dentate gyrus of epileptic mice, which were restored following FGF10 administration. Crucially, the therapeutic benefits of FGF10 were abolished in FGFR2-cKO mice, indicating that FGFR2 is essential for FGF10's effects. Conclusions Our findings demonstrate that FGF10 alleviates seizures and cognitive dysfunction in epilepsy, likely through FGFR2-dependent mechanisms involving CALB1 modulation. These results highlight FGF10 as a potential therapeutic target for epilepsy, offering a novel strategy for improving treatment outcomes in patients with TLE.
- 3 June 2025
- Published by Elsevier in Microbial Pathogenesis
- Vol. 206, 107768
Prevotella histicola suppress olfactory bulb damage caused by LPS-induced rhinitis in mice
- 3 June 2025
- Published by Elsevier in Microbial Pathogenesis
- Vol. 206, 107768
Prevotella histicola suppress olfactory bulb damage caused by LPS-induced rhinitis in mice
- Top Cited PapersOpen Access
- 17 February 2025
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 31 (2) , e70238
Astaxanthin Inhibits Ferroptosis of Hippocampal Neurons in Kainic Acid‐Induced Epileptic Mice by Activating the Nrf2/ GPX4 Signaling Pathway
Background: Epilepsy, a prevalent neurological disorder, is distinguished by episodic abnormal discharges of neurons within the brain, resulting in transient brain dysfunction. Prior research has identified a novel form of cell death termed ferroptosis, which is intricately linked to the initiation and progression of epilepsy. It has been demonstrated that astaxanthin (AST) can inhibit ferroptosis by enhancing the activity of nuclear factor erythroid 2‐related factor 2 (Nrf2), thereby providing cytoprotection. Therefore, this study aims to investigate whether AST can alleviate neuronal ferroptosis in epilepsy by activating the Nrf2/GPX4 pathway, thereby exerting a neuroprotective effect. Methods: By constructing a kainic acid (KA)‐induced epilepsy mouse model and a KA‐induced HT22 cell model, we employed behavioral testing, Western blot analysis, quantitative real‐time reverse transcription qRT‐PCR, ferroptosis‐related assay kits, immunofluorescence staining, and other methods. These methodologies were utilized to investigate the protective effects and underlying mechanisms of AST on ferroptosis in KA‐induced epileptic mice and HT22 neurons. Results: Our results demonstrate that AST pretreatment alleviates KA‐induced epileptic behaviors and cognitive impairments in mice and mitigates ferroptosis indicators such as lipid peroxidation and mitochondrial morphological alterations. This neuroprotective effect appears to be mediated by the activation of the Nrf2/GPX4 signaling axis. In vitro studies further revealed that AST confers neuroprotection against KA‐induced HT22 neuronal cell death, an effect that is abrogated by an Nrf2 inhibitor. Hence, the neuroprotective properties of AST are significantly associated with the modulation of the Nrf2‐mediated ferroptosis pathway, as corroborated by bioinformatics analyses. Conclusion: The AST effectively inhibits neuronal ferroptosis in both in vivo and in vitro epilepsy models via the Nrf2/GPX4 pathway. This finding suggests that AST holds promise as a potential therapeutic agent for the treatment of epilepsy.
- 17 February 2025
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 31 (2) , e70238
Top Cited PapersOpen AccessAstaxanthin Inhibits Ferroptosis of Hippocampal Neurons in Kainic Acid‐Induced Epileptic Mice by Activating the Nrf2/ GPX4 Signaling Pathway
Background: Epilepsy, a prevalent neurological disorder, is distinguished by episodic abnormal discharges of neurons within the brain, resulting in transient brain dysfunction. Prior research has identified a novel form of cell death termed ferroptosis, which is intricately linked to the initiation and progression of epilepsy. It has been demonstrated that astaxanthin (AST) can inhibit ferroptosis by enhancing the activity of nuclear factor erythroid 2‐related factor 2 (Nrf2), thereby providing cytoprotection. Therefore, this study aims to investigate whether AST can alleviate neuronal ferroptosis in epilepsy by activating the Nrf2/GPX4 pathway, thereby exerting a neuroprotective effect. Methods: By constructing a kainic acid (KA)‐induced epilepsy mouse model and a KA‐induced HT22 cell model, we employed behavioral testing, Western blot analysis, quantitative real‐time reverse transcription qRT‐PCR, ferroptosis‐related assay kits, immunofluorescence staining, and other methods. These methodologies were utilized to investigate the protective effects and underlying mechanisms of AST on ferroptosis in KA‐induced epileptic mice and HT22 neurons. Results: Our results demonstrate that AST pretreatment alleviates KA‐induced epileptic behaviors and cognitive impairments in mice and mitigates ferroptosis indicators such as lipid peroxidation and mitochondrial morphological alterations. This neuroprotective effect appears to be mediated by the activation of the Nrf2/GPX4 signaling axis. In vitro studies further revealed that AST confers neuroprotection against KA‐induced HT22 neuronal cell death, an effect that is abrogated by an Nrf2 inhibitor. Hence, the neuroprotective properties of AST are significantly associated with the modulation of the Nrf2‐mediated ferroptosis pathway, as corroborated by bioinformatics analyses. Conclusion: The AST effectively inhibits neuronal ferroptosis in both in vivo and in vitro epilepsy models via the Nrf2/GPX4 pathway. This finding suggests that AST holds promise as a potential therapeutic agent for the treatment of epilepsy.
- 18 January 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 164, 110251
Butylphthalide may inhibit blood–brain barrier disruption through complement-related pathways to alleviate cognitive impairment in epileptic mice
- 18 January 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 164, 110251
Butylphthalide may inhibit blood–brain barrier disruption through complement-related pathways to alleviate cognitive impairment in epileptic mice
- Open Access
- 31 December 2024
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 24 (1) , 1-12
Development and internal validation of a prognostic model for predicting tonic-clonic seizures during pregnancy in women with epilepsy
We aim to develop a model to predict the probability of tonic-clonic seizures in women with epilepsy (WWE) at any point during pregnancy until six weeks postpartum. We conducted a screening of patients diagnosed with epilepsy and who were pregnant, at a tertiary hospital in China, during the period of 1 January 2010 to 31 December 2020. We then followed up with these patients for at least one year postpartum. A total of 271 eligible patients were included in the cohort. The outcome was the occurrence of a tonic-clonic seizure during pregnancy or within six weeks postpartum. Predictors were screened through univariate analysis, and models were fitted through multivariate logistic regression analysis. Further, we compared the WMU model with the AntiEpileptic drug Monitoring in PREgnancy (EMPiRE) model in terms of discrimination (the area under receiver operating characteristic curve [AUC]), accuracy (GiViTI calibration belt), decision curve analysis (DCA), net reclassification index (NRI), and integrated discrimination improvement (IDI). Finally, we plotted a nomogram of the WMU model. Of the 271 pregnant WWE, 62 patients (22.9%) had the outcome. The WMU model included three predictors: age at the time of pregnancy, admission to hospital for seizures in previous pregnancy, and seizures in the 12 months before pregnancy. Compared to the EMPiRE model, the AUC value of the WMU model was higher (0.76 vs. 0.639, P < 0.05). GiViTI calibration belt showed that the predicted risks of the WMU model were mostly consistent with the observed risks. In terms of DCA, the WMU model revealed the highest net proportional benefit for predicted probability thresholds between 10% and 90%. Additionally, our model exhibited better reclassification performance than the EMPiRE model (NRI: 0.331, P < 0.01 and IDI: 0.129, P < 0.01). We attempted to develop a prognostic model for predicting the risk of tonic-clonic seizures in pregnant WWE. The WMU model showed good performance, but without external validation, it is unclear whether WMU model could be generalized.
- 31 December 2024
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 24 (1) , 1-12
Open AccessDevelopment and internal validation of a prognostic model for predicting tonic-clonic seizures during pregnancy in women with epilepsy
We aim to develop a model to predict the probability of tonic-clonic seizures in women with epilepsy (WWE) at any point during pregnancy until six weeks postpartum. We conducted a screening of patients diagnosed with epilepsy and who were pregnant, at a tertiary hospital in China, during the period of 1 January 2010 to 31 December 2020. We then followed up with these patients for at least one year postpartum. A total of 271 eligible patients were included in the cohort. The outcome was the occurrence of a tonic-clonic seizure during pregnancy or within six weeks postpartum. Predictors were screened through univariate analysis, and models were fitted through multivariate logistic regression analysis. Further, we compared the WMU model with the AntiEpileptic drug Monitoring in PREgnancy (EMPiRE) model in terms of discrimination (the area under receiver operating characteristic curve [AUC]), accuracy (GiViTI calibration belt), decision curve analysis (DCA), net reclassification index (NRI), and integrated discrimination improvement (IDI). Finally, we plotted a nomogram of the WMU model. Of the 271 pregnant WWE, 62 patients (22.9%) had the outcome. The WMU model included three predictors: age at the time of pregnancy, admission to hospital for seizures in previous pregnancy, and seizures in the 12 months before pregnancy. Compared to the EMPiRE model, the AUC value of the WMU model was higher (0.76 vs. 0.639, P < 0.05). GiViTI calibration belt showed that the predicted risks of the WMU model were mostly consistent with the observed risks. In terms of DCA, the WMU model revealed the highest net proportional benefit for predicted probability thresholds between 10% and 90%. Additionally, our model exhibited better reclassification performance than the EMPiRE model (NRI: 0.331, P < 0.01 and IDI: 0.129, P < 0.01). We attempted to develop a prognostic model for predicting the risk of tonic-clonic seizures in pregnant WWE. The WMU model showed good performance, but without external validation, it is unclear whether WMU model could be generalized.
- 31 December 2024
- Published by Elsevier in Epilepsy & Behavior
- Vol. 163, 110235
Development of a nomogram model for early prediction of refractory convulsive status epilepticus
- 31 December 2024
- Published by Elsevier in Epilepsy & Behavior
- Vol. 163, 110235
Development of a nomogram model for early prediction of refractory convulsive status epilepticus